ClinicalTrials.gg
TerminatedNCT02631603chILD-EU_EAAUpdated Dec 18, 2024Results posted

Stop Exogenous Allergic Alveolitis (EAA) in Childhood

A Phase 2 interventional study of Placebo and Prednisolone in Hypersensitivity Pneumonitis and Exogenous Allergic Alveolitis, sponsored by Matthias Griese. Terminated at 7 sites in Germany. Open to participants aged 6 Years to 25 Years. Per ClinicalTrials.gov, last updated 2024-12-18.

Sponsored by Matthias Griese · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
After several years of recruitment only 4 patients were included. Study timelines for study completition too long. Decided to terminate trial.

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Apr 2015, registered Nov 2015).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
4
Allocation
Randomized
Ages
6 Years to 25 Years
Sex
All
01

Study summary

Stop exogenous allergic alveolitis (EAA) or hypersensitivity pneumonitis in childhood: healthy into adulthood - a randomized, double-blind, placebo-controlled, parallel-group study to evaluate prednisolone treatment and course of disease.

The hypothesis of the study is that the treatment with placebo will not be inferior in terms of Forced Vital Capacity (FVC) improvement than treatment with systemic steroids after 6 months treatment.

Read the detailed description

After an initial steroid pulse given to all patients, patients will be allocated to the two treatments, i.e., oral prednisolone and Placebo.

Experimental intervention: Placebo Control intervention: Prednisolone Duration of intervention per patient: 3 months Follow-up per patient: 3 months

Primary Objective:

To evaluate outcome of EAA at 6 months and compare the medium term treatment with systemic steroids or placebo.

Secondary Objectives:

To evaluate the completeness and knowledge of standardized and pedantic allergen elimination in families with a child with EAA.

To evaluate the treatment of EAA with systemic steroids compared to placebo at 3 months.

To evaluate the safety of the treatment of EAA with outpatient usage of systemic steroids compared to Placebo.

02

Conditions studied

  • Hypersensitivity Pneumonitis
  • Exogenous Allergic Alveolitis

Keywords

  • Children
  • Birds
  • Moulds
03

In context

Alveolitis, Extrinsic Allergic

34 studies on the registry are indexed under Alveolitis, Extrinsic Allergic; 11 are open to participants now.

This study's enrollment of 4 is below the median of 51 across 16 interventional studies indexed under Alveolitis, Extrinsic Allergic.

Browse Alveolitis, Extrinsic Allergic studies →

Lead sponsor

Matthias Griese is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Newly or previously diagnosed but not appropriately treated EAA in children, adolescents and young adults, aged between 3 and 25 years. The diagnosis of EAA must be confirmed by independent review of the findings by an expert panel and must be based on the presence of at least 4 of the following findings:

    • History of appropriate allergen exposure
    • Restrictive lung function (FVC \< 80% predicted for age and FVC/ \< 1) testing, if appropriate for age (usually > 5 y)
    • Positive serum precipitins for bird/fungus exposed to (other allergens have rarely, if every been demonstrated in children)
    • Lymphocytosis in BAL (> 20% of cells are lymphocytes)
    • HRCT showing the characteristic nodular, linear or reticular opacities, and ground glass pattern with increased attenuation.
    • Lung demonstrating lymphocytic alveolitis, bronchiolitis, and non-caseating histiocytic granulomatas.
    • Controlled allergen exposure followed by characteristic reaction, including fever, coughing, restriction on lung function, hypoxemia/desaturation at rest or with exercise
  2. Unchanged inhaled if on; if off, no plans to introduce them in the following 6 months
  3. Agreement to home visit by independent study physician

Exclusion criteria

Exclusion Criteria:

  1. for usage systemic
  2. Critically ill patients needing respiratory support
  3. Non-compliance with medical treatments and interventions
  4. Women with and not practicing a medically accepted during the trial and a positive pregnancy test (serum or urine) before and at the end of the trial. Reliable contraception are systematic contraceptives (oral, implant, injection) and diaphragm or condoms with spermicide.
  5. Pregnancy and lactation.
  6. Participation in another trial for EAA during the last 4 weeks or not beyond the time of 4 half-lives of the medication used. In the unlikely event a subject is already in another clinical study but not for EAA, that study must be stopped and the subject may be treated according to this protocol; a latency time between the two studies does not appear reasonable, as acute intervention is necessary for EAA. Treatment may be best done in the frame work of this protocol.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Placebo

    Capsules of placebo will be taken for 3 months, same schedule as verum.

    Drug: Placebo

  • Active comparator
    Prednisolone

    Oral prednisolone, anticipated dose: first month 0.5 mg/kg bw/d, second month 0.25 mg/kg bw/d, and third month 0.125 mg/kg bw/d in a single morning dose. Individual capsules will be prepared using rounded dose.

    Drug: Prednisolone

Interventions

  • DrugPlacebo

    Administer Placebo as anti-inflammatory

    Also known as: no other name

  • Administer Prednisolone as anti-inflammatory

    Also known as: Decortin H

06

What researchers measure

Primary outcomes

  1. Forced Vital Capacity (FVC).

    The relative change from baseline through month 6 compared to change from placebo of FVC.

    Time frame: 6 months

Secondary outcomes

  1. Forced Vital Capacity (FVC)

    FVC measured in accordance to standarized protocol.

    Time frame: 3 months

07

Results

Posted Dec 18, 2024
Limitations and caveats
The major limitation of this trial was its premature closure and the small number of patients included. This was due to several reasons: the study design was developed as work package within a limited research project. The anticipated enrolment was lower than expected. There was a lack of resources to carry on the clinical trial for the many years in view of the much lower incidences of this rare conditions than calculated before on available data.

Participant flow

Originally, it was planned to screen 60 subjects to include approximately 40 patients. From January 2015 to July 2016 due to difficulties in funding only 4 children were included in the trial. All met inclusion criteria, were randomized, and completed the trial.

Participant flow — Overall Study
MilestonePlaceboPrednisolone
Started13
Completed13
Not completed00

Outcome measures

PrimaryForced Vital Capacity (FVC).

The relative change from baseline through month 6 compared to change from placebo of FVC.

Time frame:
6 months
Reported as:
Number · % predicted
Forced Vital Capacity (FVC).
% predictedPrednisolone 1PlaceboPrednisolone 2Prednisolone 3
Forced Vital Capacity (FVC).1261038465
SecondaryForced Vital Capacity (FVC)

FVC measured in accordance to standarized protocol.

Time frame:
3 months
Reported as:
Number · % predicted
Forced Vital Capacity (FVC)
% predictedPrednisolone 1PlaceboPrednisolone 2Prednisolone 3
Forced Vital Capacity (FVC)114958576

Adverse events

Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/1 (0%)0/1 (0%)1/1 (100%)
Prednisolone0/3 (0%)0/3 (0%)3/3 (100%)
Most frequent other events
Most frequent other events
EventPlaceboPrednisolone
Fever, headache, haematome, tiredness, hypertensionGeneral disorders1/12/3
ConjunctivitisEye disorders1/11/3
Cushing habitus, hair growth, weight gainEndocrine disorders1/11/3
Respiratory tract infection, candidiasisInfections and infestations0/12/3
GastritisGastrointestinal disorders0/11/3

Baseline characteristics

Age, Customized
Age, Customized(years)Prednisolone 1PlaceboPrednisolone 2Prednisolone 3Total
Number8.46.610.612.99.6
Sex: Female, Male
Sex: Female, Male(Participants)Prednisolone 1PlaceboPrednisolone 2Prednisolone 3Total
Female01102
Male10012
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Prednisolone 1PlaceboPrednisolone 2Prednisolone 3Total
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White11114
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)Prednisolone 1PlaceboPrednisolone 2Prednisolone 3Total
Germany11114
O2 saturation at rest
O2 saturation at rest(%)Prednisolone 1PlaceboPrednisolone 2Prednisolone 3Total
Number90981009796.3
08

Study locations

7 sites
  • Klinikum der Universität München, Haunersches Kinderspital
    München, Bayern 80337, Germany
  • Universitätsklinikum Frankfurt, Pneumologie, Allergologie, Mukoviszidose
    Frankfurt, Hessen 60590, Germany
  • Justus-Liebig-Universität, Allgemeine Pädiatrie u. Neonatologie
    Gießen, Hessen 35385, Germany
  • Medizinische Hochschule Hannover
    Hannover, Niedersachsen 30625, Germany
  • Klinik für Kinder- und Jugendmedizin der Ruhr-Universität Bochum im St. Josef-Hospital
    Bochum, Nordrhein-Westfalen 44791, Germany
  • Uniklinikum Essen, Pädiatrische Pneumologie
    Essen, Nordrhein-Westfalen 45122, Germany
  • Klinik u. Poliklinik für Kinder- u. Jugendmedizin der Universität Leipzig
    Leipzig, Sachsen 04103, Germany
09

References and documents

Publications

  • Griese M, Stehling F, Schwerk N, Rosewich M, Jerkic PS, Rock H, Ruckes C, Kronfeld K, Sebah D, Wetzke M, Seidl E. Hypersensitivity pneumonitis: Lessons from a randomized controlled trial in children. Pediatr Pulmonol. 2021 Aug;56(8):2627-2633. doi: 10.1002/ppul.25513. Epub 2021 May 28. PubMed 34048641 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Equivalent to product information sheet

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2015 to primary completion in Jul 2016, 15 months.

Results were first posted in Dec 2024, 8 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2015
First posted
Dec 16, 2015
StartActual
Apr 2015
Primary completionActual
Jul 11, 2016
CompletionActual
Jun 16, 2020
Results first posted
Dec 18, 2024
Last update
Dec 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02631603
Lead sponsor
Matthias Griese
Responsible party
Matthias Griese (Prof. Dr. med., Ludwig-Maximilians - University of Munich) — Sponsor-investigator
First posted
Dec 16, 2015
Start date
Apr 2015
Primary completion
Jul 11, 2016
Completion
Jun 16, 2020
Results posted
Dec 18, 2024
Last update
Dec 18, 2024

Study contacts

Matthias Griese, Prof., MD
study director · Pediatric Pneumology, Ludwig-Maximilians-University Munich
Meike Hengst, MD
principal investigator · Pediatric Pneumology, Ludwig-Maximilians University Munich

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion